Miracle-dz/UniFAR-FTUs huggingface dataset:
Mitigating the negative effects of retrieval stress on memory: an arousal reappraisal intervention

ABSTRACT In a preregistered experiment, we examined the efficacy of arousal reappraisal as an intervention for reducing the negative effects of stress at retrieval on memory. Participants (N = 177) were semi-randomly assigned to one of three conditions: a Stress-intervention condition, a Stress-placebo condition, and a No-stress-placebo control condition. Participants viewed four images of complex, mildly negatively valenced scenes. One day later, they received an arousal reappraisal intervention or placebo before exposure to a laboratory stressor (or a control version for the No-stress condition). Participants were then tested on their memory of the images using a free recall instruction and multiple-choice recognition questions. As expected, negative affect and blood pressure increased for the stress conditions but not the control condition. Contrary to our hypotheses, memory performance did not statistically significant differ between the Stress-placebo condition and the No-stress-placebo control condition, indicating a lack of negative effects of acute retrieval stress on memory. Furthermore, we also found no statistically significant differences between the Stress-intervention condition and Stress-placebo condition in terms of memory performance, suggesting that the intervention did not assist with enhancing memory. We integrate interpretations of the findings from this study with a discussion of avenues for future research in this area.
Lindsleyite (Ba) and mathiasite (K): two new chromium-titanates in the crichtonite series from the upper mantle

Two new opaque minerals are described from metasomatized peridotites and heavy media concentrates from four kimberlites in the Republic of South Africa. Lindsleyite and mathiasite are the Ba and K members of the AM2lO3s series, characterized by predominant A-specific, large cations (Sr = crichtonite; Na : landauite; Pb = senaite; ca = loveringite, and U + REE : davidite), and by M-formula small cations which are dominantly Ti, cr, Fe, Mg, Zr, and Nb. Approximately TOVI of the A-site is fitled by either Ba or K in the new minerals, and selective solid solution is present with Ba-Sr and K-Ca exchange. Typical electron microbeam analyses based on 38 oxygens, give the following formulae: lindsleyite: A = Ban.62Srs a1Ca6.sePb6. e1Ke sTNaa.s6REEs q3 M : Ti1 1.62rs. 67A16. 1 1 Cr3.seFe2. s7Mg 1 aqNbo.os mathiasite: A = Ifu.ooCao 22516. ;5Baa roNao.osREEo. os M : Ti 1 3. 16Zrs 62Ct237F a2.zaMg r.o:Cao.zzNbo oq REE in both minerals share the unusual characteristic of davidite and loveringite in possessing LREE- and HREE-enrichment, with depletion of the middle lanthanides. The space group for both minerals is R3 or R3 and the strongest reflections are 2.13, 1.80, 1.59, and 1.444 (all100) for lindsleyite, and 2.25(90),2.14 (100), and 1.44 A (tOO) for mathiasite. Hexagonal unit cell parameters for lindsleyite are a : 1.037 nm, c = 2.052 nm, V : l.9ll nm3, and for mathiasite are a = 1.035 nm, c : 2.058 nm, V = 1.909 nm3. Calculated densities for the Ba and K members are 4.63 and 4.60 gm. /cm3, respectively. Both minerals are black and have a metallic luster and conchoidal fracture. The minerals are pale tan in reflected light, exhibit weak reflection pleochroism and weak-moderate reflection anisotropy. Spectral reflectances for lindsleyite and mathiasite are very similar and are comparable to ilmenite and rutile. R1 and R2 in air and oil, respectively, for lindsleyite are: 470 nm = 17.9-183%,5.9-6.1%; 546 nm : 17.0-17.3%;5.3-5.5%;589 nm : 16-7-17.Uvo,5.1-5.3%;650 nm : 16.5-16.9vo,5.0-5.2%. Similar data for mathiasite are:
Changes in Family Poverty Status and Child Health

In this study, we capture the impact of poverty at birth, cumulative poverty, and transition into and out of poverty on child weight status, asthma, and HRQoL. OBJECTIVES: In this study, we aim to assess the associations over time between poverty and child weight status, asthma, and health-related quality of life (HRQoL). METHODS: We analyzed data for 3968 children from the Generation R Study, a population-based cohort study in the Netherlands. Net household income and the number of adults and children living from this income were measured at 4 time-points (during pregnancy and at ages 2, 3, and 6). Poverty was defined on the basis of the equivalized household income being <60% of the median national income. Child health outcomes were measured at age 6 years. The association was explored by using logistic and linear regression models. RESULTS: In this cohort, 9.8% of children were born into poverty and 6.0% had experienced 3 to 4 episodes of poverty. Independent of current poverty status, children born into poverty had an odds ratio (OR) of 1.68 for having overweight/obesity and a lower physical HRQoL (OR = −1.32) than those not born into poverty. Children having experienced 3 to 4 episodes of poverty had an OR of 1.94 for having asthma and a lower physical HRQoL (OR = −3.32) compared with children from never-poor families. Transition out of poverty before age 2 was associated with lower risk of asthma and a higher physical HRQoL compared with children who remained in poverty. CONCLUSIONS: Being born into poverty or experiencing multiple episodes of poverty is associated with negative child health outcomes, such as having overweight, asthma, or a lower HRQoL. Support for children and families with a low household income is warranted.
Remote Measurement in Rheumatoid Arthritis: Qualitative Analysis of Patient Perspectives

Background Rheumatoid arthritis (RA) is characterized by recurrent fluctuations in symptoms such as joint pain, swelling, and stiffness. Remote measurement technologies (RMTs) offer the opportunity to track symptoms continuously and in real time; therefore, they may provide a more accurate picture of RA disease activity as a complement to prescheduled general practitioner appointments. Previous research has shown patient interest in remote symptom tracking in RA and has provided evidence for its clinical validity. However, there is a lack of co-design in the current development of systems, and the features of RMTs that best promote optimal engagement remain unclear. Objective This study represents the first in a series of work that aims to develop a multiparametric RMT system for symptom tracking in RA. The objective of this study is to determine the important outcomes for disease management in patients with RA and how these can be best captured via remote measurement. Methods A total of 9 patients (aged 23-77 years; mean 55.78, SD 17.54) with RA were recruited from King’s College Hospital to participate in two semistructured focus groups. Both focus group discussions were conducted by a facilitator and a lived-experience researcher. The sessions were recorded, transcribed, independently coded, and analyzed for themes. Results Thematic analysis identified a total of four overarching themes: important symptoms and outcomes in RA, management of RA symptoms, views on the current health care system, and views on the use of RMTs in RA. Mobility and pain were key symptoms to consider for symptom tracking as well as symptom triggers. There is a general consensus that the ability to track fluctuations and transmit such data to clinicians would aid in individual symptom management and the effectiveness of clinical care. Suggestions for visually capturing symptom fluctuations in an app were proposed. Conclusions The findings support previous work on the acceptability of RMT with RA disease management and address key outcomes for integration into a remote monitoring system for RA self-management and clinical care. Clear recommendations for RMT design are proposed. Future work will aim to take these recommendations into a user testing phase.
Relationships between energy balance during early lactation and cow performance, blood metabolites, and fertility: A meta-analysis of individual cow data.

This study was designed to contribute to the understanding of the relationships between energy balance (EB) in early lactation [4 to 21 d in milk (DIM)] and fertility traits [interval to start of luteal activity (SLA), interval to first observed heat (FOH), and conception to first artificial insemination (AI)], and their associated relationships with cow performance and blood metabolites between 4 to 150 DIM. Individual cow data (488 primiparous and 1,020 multiparous lactations) from 27 experiments was analyzed. Data on cow performance, EB (on a metabolizable energy basis), and fertility traits were available for all cows, whereas milk progesterone data (to determine SLA) and periodic blood metabolite data were available for 1,042 and 1,055 lactations, respectively. Data from primiparous and multiparous cows were analyzed separately, with the data sets for the 2 parity groups divided into quartiles (Q1-Q4) according to the average EB during 4 to 21 DIM (EB range for Q1 to Q4: primiparous, -120 to -49, -49 to -24, -24 to -3, and -3 to 92 MJ/d, respectively: multiparous, -191 to -79, -79 to -48, -48 to -22, and -22 to 93 MJ/d, respectively). Differences between EB quartiles for production and fertility traits were compared. In early lactation (4 to 21 DIM), moving from Q1 to Q4 mean DMI and metabolizable energy intake increased whereas mean ECM decreased. During the same period, moving from Q1 to Q4 milk fat content, milk fat-to-protein ratio, and plasma nonesterified fatty acid and β-hydroxybutyrate concentrations decreased, whereas milk protein content and plasma glucose concentrations increased in both primiparous and multiparous cows. When examined over the entire experimental period (4 to 150 DIM), many of the trends in intakes and milk production remained, although the magnitude of the difference between quartiles was much reduced, whereas milk fat content did not differ between quartiles in primiparous cows. The percentage of cows with FOH before 42 DIM increased from Q1 to Q4 (from 46 to 72% in primiparous cows, and from 41 to 58% in multiparous cows). Interval from calving to SLA and to FOH decreased with increasing EB during 4 to 21 DIM, with these occurring 9.8 and 10.2 d earlier, respectively, in Q4 compared with Q1 (primiparous cows), and 7.4 and 5.9 d earlier, respectively, in Q4 compared with Q1 (multiparous cows). For each 10 MJ/d decrease in mean EB during 4 to 21 DIM, FOH was delayed by 1.2 and 0.8 d in primiparous and multiparous cows, respectively. However, neither days to first AI nor the percentage of cows that conceived to first AI were affected by daily EB during 4 to 21 DIM in either primiparous or multiparous cows, and this is likely to reflect a return to a less metabolically stressed status at the time of AI. These results demonstrate that interval from calving to SLA and to FOH were reduced with increasing EB in early lactation, whereas early lactation EB had no effect on conception to the first service.
Detection of C Reactive Protein (CRP) in Serum by an Electrochemical Aptamer‐Based Sandwich Assay

A disposable electrochemical assay involving magnetic particles and carbon-based screen-printed electrodes (SPCEs) was developed for the detection of C Reactive Protein (CRP). CRP is a plasma protein and is among the most expressed proteins in acute phase inflammation cases, being a known biomarker for inflammatory states. The assay was based on a sandwich format in which a RNA aptamer was coupled to a monoclonal antibody and alkaline phosphatase (AP) was used as enzymatic label. After the sandwich assay, the modified magnetic beads were captured by a magnet on the surface of a graphite working electrode and the electrochemical detection was thus achieved through the addition of the AP substrate (α-naphthyl-phosphate) and α-naphthol produced during the enzymatic reaction was detected using differential pulse voltammetry (DPV). The parameters influencing the different steps of the assay were optimized in order to reach the best sensitivity and specificity. With the optimized conditions, the assay was applied to the analysis of CRP free serum and serum samples.
Danger! Negative memories ahead: the effect of warnings on reactions to and recall of negative memories

ABSTRACT A trigger warning is an alert that upcoming material containing distressing themes might “trigger” the details and emotion associated with a negative memory to come to mind. Warnings supposedly prevent or minimise this distress. But, do warnings really have this effect? To simulate the experience described above, here, we examined whether warning participants—by telling them that recalling a negative event would be distressing—would change characteristics associated with the immediate and delayed recall of a negative event (such as phenomenology e.g., vividness, sense of reliving), compared to participants who we did not warn. Generally, we found that time helps to heal the “emotional wounds” associated with negative memories: negative characteristics—such as emotion, vividness etc.—faded over time. However, the event’s emotional impact (the frequency of experiences related to the event such as “I had trouble staying asleep”), subsided less over a two-week delay for participants who were warned in the first session. Our findings suggest that warning messages may prolong the negative characteristics associated with memories over time, rather than prepare people to recall a negative experience.
A pilot study evaluating GSK1070806 inhibition of interleukin-18 in renal transplant delayed graft function

Introduction Delayed graft function (DGF) following renal transplantation is a manifestation of acute kidney injury (AKI) leading to poor long-term outcome. Current treatments have limited effectiveness in preventing DGF. Interleukin-18 (IL18), a biomarker of AKI, induces interferon-γ expression and immune activation. GSK1070806, an anti-IL18 monoclonal antibody, neutralizes activated (mature) IL18 released from damaged cells following inflammasome activation. This phase IIa, single-arm trial assessed the effect of a single dose of GSK1070806 on DGF occurrence post donation after circulatory death (DCD) kidney transplantation. Methods The 3 mg/kg intravenous dose was selected based on prior studies and physiologically based pharmacokinetic (PBPK) modeling, indicating the high likelihood of a rapid and high level of IL18 target engagement when administered prior to kidney allograft reperfusion. Utilization of a Bayesian sequential design with a background standard-of-care DGF rate of 50% based on literature, and confirmed via extensive registry data analyses, enabled a statistical efficacy assessment with a minimal sample size. The primary endpoint was DGF frequency, defined as dialysis requirement ≤7 days post transplantation (except for hyperkalemia). Secondary endpoints included safety, pharmacokinetics and pharmacodynamic biomarkers. Results GSK1070806 administration was associated with IL18-GSK1070806 complex detection and increased total serum IL18 levels due to IL18 half-life prolongation induced by GSK1070806 binding. Interferon-γ−induced chemokine levels declined or remained unchanged in most patients. Although the study was concluded prior to the Bayesian-defined stopping point, 4/7 enrolled patients (57%) had DGF, exceeding the 50% standard-of-care rate, and an additional two patients, although not reaching the protocol-defined DGF definition, demonstrated poor graft function. Six of seven patients experienced serious adverse events (SAEs), including two treatment-related SAEs. Conclusion Overall, using a Bayesian design and extensive PBPK dose modeling with only a small sample size, it was deemed unlikely that GSK1070806 would be efficacious in preventing DGF in the enrolled DCD transplant population. Trial registration NCT02723786.
Interrogating lncRNA functions via CRISPR/Cas systems

ABSTRACT Long noncoding RNAs (lncRNAs) are an increasing focus of investigation due to their implications in diverse biological processes and disease. Nevertheless, the majority of lncRNAs are low in abundance and poorly conserved, posing challenges to functional studies. The CRISPR/Cas system, an innovative technology that has emerged over the last decade, can be utilized to further understand lncRNA function. The system targets specific DNA and/or RNA sequences via a guide RNA (gRNA) and Cas nuclease complex. We and others have utilized this technology in various applications such as lncRNA knockout, knockdown, overexpression, and imaging. In this review, we summarize how the CRISPR/Cas technology provides new tools to investigate the roles and therapeutic implications of lncRNAs.
Peripheral ischemic limb necrosis (Acro-ischemia) associated with severe COVID-19 patients (COVID-19 limbs): A report of three cases

The association between severe coronavirus disease 2019 and hypercoagulable state was observed in many reports. This may be explained by the presence of hypoxia, severe systemic inflammatory response, immobilization due to intensive care unit (ICU) admission, and diffuse intravascular coagulation. We report three patients who were admitted to our respiratory ICU with acute severe respiratory distress syndrome (ARDS) requiring mechanical ventilation due severe acute respiratory syndrome coronavirus 2 infection, who developed severe limb ischemia during the course of the disease.
Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19

1. Leduc C, Antoni D, Charloux A, Falcoz P-E, Quoix E. Comorbidities in the management of patients with lung cancer. Eur Respir J 2017;49:1601721. 2. McKenzie E, Hwang MK, Chan S, Zhang L, Zaki P, Tsao M, et al. Predictors of dyspnea in patients with advanced cancer. Ann Palliat Med 2018;7:427–436. 3. Mury C, Schneider AG, Nobile A, Rotman S, Liaudet L. Acute pulmonary hypertension caused by tumor embolism: a report of two cases. Pulm Circ 2015;5:577–579. 4. Humbert M, Guignabert C, Bonnet S, Dorfm€ uller P, Klinger JR, Nicolls MR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019;53:1801887. 5. Pullamsetti SS, Savai R, Seeger W, Goncharova EA. Translational advances in the field of pulmonary hypertension: from cancer biology to new pulmonary arterial hypertension therapeutics. targeting cell growth and proliferation signaling hubs. Am J Respir Crit Care Med 2017;195:425–437. 6. Savai R, Al-Tamari HM, Sedding D, Kojonazarov B, Muecke C, Teske R, et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med 2014;20:1289–1300. 7. Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, et al. Lung cancer-associated pulmonary hypertension: role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med 2017;9:eaai9048. 8. Chin M, Johns C, Currie BJ, Weatherley N, Hill C, Elliot C, et al. Pulmonary artery size in interstitial lung disease and pulmonary hypertension: association with interstitial lung disease severity and diagnostic utility. Front Cardiovasc Med 2018;5:53. 9. Toya T, Nagatomo Y, Kagami K, Yukino M, Yasuda R, Namba T, et al. Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension. Int J Cardiovasc Imaging 2019;35:1435–1442. 10. Shin S, King CS, Brown AW, Albano MC, Atkins M, Sheridan MJ, et al. Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. Respir Med 2014;108:1626–1632. 11. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al.; COPDGene Investigators; ECLIPSE Study Investigators. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012;367:913–921. 12. Moreira EM, Gall H, Leening MJ, Lahousse L, Loth DW, Krijthe BP, et al. Prevalence of pulmonary hypertension in the general population: the Rotterdam study. PLoS One 2015;10:e0130072. 13. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019;53:1801914. 14. Maron BA, Brittan EL, Hess E, Waldo SW, Bar on AE, Huang S, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020;8:873–884.
Coronavirus disease 2019 and cardiovascular complications: focused clinical review

The coronavirus disease 2019 (COVID-19) may cause not only an acute respiratory distress syndrome (ARDS) but also multiple organ damage and failure requiring intensive care and leading to death. Male sex, advanced age, chronic lung disease, chronic kidney disease and cardiovascular disease, such as hypertension, diabetes and obesity have been identified as risk factors for the COVID-19 severity. Presumably, as these three cardiovascular risk factors are associated with a high prevalence of multiorgan damage. In the present focused clinical review, we will discuss the cardiovascular complications of COVID-19 including acute cardiovascular syndrome (acute cardiac injury/COVID cardiomyopathy, thromboembolic complications and arrhythmias) and post-COVID-19 sequelae. Preliminary data shows that the cause of acute cardiovascular syndrome may be multifactorial and involve direct viral invasion of the heart and vascular system, as well as through the immune and inflammation-mediated systemic cytokine storm. COVID-19 survivors may also show persistently elevated blood pressure and sinus tachycardia at rest. Furthermore, poor diabetic control, persistent renal damage and cerebral sequelae, such as persistent cognitive and neuropsychiatric alterations are also frequently reported. A particular attention should be paid towards cardiovascular protection in COVID-19 patients who develop acute cardiovascular syndromes during hospitalization, and/or permanent/semipermanent sequelae after recovery from COVID-19. These conditions may require careful clinical assessment, treatment and close follow-up to avoid short-term and long-term complications.